v3.26.3
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of the Company's Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Summary of Significant Accounting Policies [Line Items]                
General and administrative expenses $ 10,982     $ 2,827     $ 28,211 $ 8,273
Research and development expenses                
Total research and development expenses 51,516     2,419     110,307 8,261
Total operating loss (62,498)     (5,246)     (138,518) (16,534)
Non-operating income 3,432     1,690     8,795 2,801
Net loss (59,066) $ (51,603) $ (19,054) (3,556) $ (4,871) $ (5,306) (129,723) (13,733)
Operating Segments [Member]                
Summary of Significant Accounting Policies [Line Items]                
General and administrative expenses 10,982     2,827     28,211 8,273
Research and development expenses                
Total direct research and development expenses 46,171     1,132     96,377 3,409
Total indirect and unallocated research and development expenses 5,345     1,287     13,930 4,852
Total research and development expenses 51,516     2,419     110,307 8,261
Total operating loss (62,498)     (5,246)     (138,518) (16,534)
Non-operating income 3,432     1,690     8,795 2,801
Net loss (59,066)     (3,556)     (129,723) (13,733)
Schizophrenia programs | Operating Segments [Member]                
Research and development expenses                
Total direct research and development expenses 36,394     25     73,635 512
Bipoar depression programs | Operating Segments [Member]                
Research and development expenses                
Total direct research and development expenses 2,753     57     8,425 57
Formulation and CMC | Operating Segments [Member]                
Research and development expenses                
Total direct research and development expenses 2,995     1,044     8,300 2,717
Preclinical and other direct expenses | Operating Segments [Member]                
Research and development expenses                
Total direct research and development expenses 4,029     6     6,017 123
Personnel-related | Operating Segments [Member]                
Research and development expenses                
Total indirect and unallocated research and development expenses 4,720     837     12,054 3,154
Consulting and other | Operating Segments [Member]                
Research and development expenses                
Total indirect and unallocated research and development expenses $ 625     $ 450     $ 1,876 $ 1,698